Welcome to our dedicated page for Axsome Therapeut news (Ticker: AXSM), a resource for investors and traders seeking the latest updates and insights on Axsome Therapeut stock.
Axsome Therapeutics, Inc. reports news on its biopharmaceutical business focused on central nervous system disorders, including marketed medicines and late-stage neuroscience programs. Company updates commonly cover FDA actions, product revenue for AUVELITY, SUNOSI and SYMBRAVO, business results, investor presentations, and development activity in neurological and psychiatric conditions.
Recurring topics include AUVELITY for major depressive disorder and agitation associated with dementia due to Alzheimer’s disease, SUNOSI for excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, migraine treatment commercialization, and pipeline work involving solriamfetol, AXS-12 and PDE10A inhibitor programs.
Axsome Therapeutics (NASDAQ: AXSM) is supporting educational initiatives during Migraine and Headache Awareness Month in June 2026. The company is backing the first annual Headache in the City campaign on June 15 in New York City and lighting its One World Trade Center headquarters purple on June 4 to promote migraine awareness.
Axsome is also amplifying patient resources from leading migraine advocacy organizations, including tools to find specialists, explainer videos, financial assistance guides, and educational podcasts.
Axsome Therapeutics (NASDAQ: AXSM) announced participation in several June 2026 investor conferences, featuring fireside chats at events hosted by William Blair, Jefferies, Goldman Sachs, Oppenheimer, and UBS.
Live webcasts for select sessions and 30-day replays will be available via the company’s investor relations website.
Axsome Therapeutics (NASDAQ: AXSM) is presenting new AUVELITY and solriamfetol data in major depressive disorder and obstructive sleep apnea at the ASCP 2026 Annual Meeting in Miami from May 26-29.
The company will share multiple poster presentations focused on anxious distress, anxiolytic effects, real-world outcomes, and neuropsychological measures.
Axsome Therapeutics (NASDAQ: AXSM) recognized Mental Health Month on May 7, 2026, aligning with the "More Good Days Together" theme and sharing mental‑health resources for patients, families, and communities. Axsome highlighted nonprofit tools, therapy‑finder platforms, crisis resources including the 988 Lifeline, and awareness activities.
Axsome Therapeutics (NASDAQ: AXSM) will participate in two investor conferences in May 2026: a BofA Securities Health Care Conference fireside chat on May 12, 2026 at 8:40 a.m. PT in Las Vegas, and an RBC Capital Markets Global Healthcare Conference fireside chat on May 19, 2026 at 1:35 p.m. ET in New York.
Live webcasts will be available on the company’s Investors > Webcasts & Presentations page at axsome.com, with replays posted for approximately 30 days after each event.
Axsome Therapeutics (NASDAQ: AXSM) reported Q1 2026 net product revenue of $191.2M, up 57% year-over-year, driven by AUVELITY $153.2M (+59% YoY), SUNOSI $33.9M (+34% YoY) and SYMBRAVO $4.1M. AUVELITY received FDA approval for agitation associated with dementia due to Alzheimer’s disease and full commercial launch is on track for June 2026. Q1 net loss was $64.5M (−$1.26/share). Cash and cash equivalents totaled $305.1M at March 31, 2026.
Axsome Therapeutics (NASDAQ: AXSM) announced an investor event on May 1, 2026 at 8:00 AM ET discussing the U.S. FDA approval of AUVELITY (dextromethorphan HBr and bupropion HCl) for treatment of agitation associated with dementia due to Alzheimer’s disease.
AUVELITY is described as a first-in-class treatment targeting NMDA and sigma-1 receptors. Dr. Jeffrey Cummings will provide clinical perspective; management will review the drug and anticipated commercial plans. A live webcast and 30-day replay are available on the company website.
Axsome (NASDAQ: AXSM) announced FDA approval of AUVELITY (dextromethorphan HBr and bupropion HCl) on April 30, 2026, for the treatment of agitation associated with dementia due to Alzheimer’s disease.
The approval is supported by Phase 3 ADVANCE-1 and long-term ACCORD-2 data showing statistically significant improvement on the CMAI and longer time to relapse; AUVELITY has been administered to >300,000 patients to date.
Axsome Therapeutics (NASDAQ: AXSM) will report first quarter 2026 financial results on May 4, 2026 before U.S. markets open and host a conference call at 8:00 a.m. ET.
Investors can join via domestic dial-in (877) 405-1239, international +1 (201) 389-0851, or a live webcast on the company’s Investors > Webcasts & Presentations page. A replay will be available on the website for about 30 days after the event.
Axsome Therapeutics (NASDAQ: AXSM) acquired exclusive global rights to balipodect (TAK-063), a selective PDE10A inhibitor aimed at schizophrenia and Tourette syndrome.
Balipodect completed a 164-patient Phase 2 proof-of-concept in schizophrenia and has been studied in over 360 individuals; Axsome plans Phase 3 trial-enabling activities in 2026. Takeda received an upfront payment plus potential milestone and royalty payments.